Explore
Trendline
Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication
Bank of America Commits $250 Million Annually to Employee Weight-Loss Medication
Read More
Trendline
Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees
Bank of America Invests $250 Million Annually in GLP-1 Weight-Loss Medications for Employees
Read More
Trendline
Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs
Bank of America Invests $250 Million Annually in Employee Health with GLP-1 Drugs
Read More
Trendline
Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs
Bank of America Allocates $250 Million Annually for Employee Weight Loss Drugs
Read More
USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says
Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Read More
Trendline
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health
Read More
Trendline
GLP-1 Medications Transforming Health Beyond Weight Loss
GLP-1 Medications Transforming Health Beyond Weight Loss
Read More
Trendline
Bank of America Warns of Extreme Bullish Sentiment, Advises Caution
Bank of America Warns of Extreme Bullish Sentiment, Advises Caution
Read More
Trendline
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits
Bank of America Invests $250 Million Annually in GLP-1 Drugs for Employee Health Benefits
Read More
Trendline
Bank of America Allocates $250 Million Annually for Employee GLP-1 Drugs
Bank of America Allocates $250 Million Annually for Employee GLP-1 Drugs
Read More
Trendline
Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs
Bank of America Invests Over $250 Million in Employee Health with GLP-1 Drugs
Read More
Trendline
Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales
Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales
Read More